[Mobitz type II block during one-lung ventilation].

Masui

Department of Anesthesiology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898.

Published: March 2010

We present a case of Mobitz type II atrioventricular block during one-lung ventilation in a 74-year-old man with lung cancer under anesthesia. Premedication with atropine 0.5 mg and midazolam 2 mg intramuscularly were given 30 min before entering the operating room. Before anesthesia, his heart rate was 72 beats x min(-1) with normal sinus rhythm and blood pressure was 120/70 mmHg. An epidural catheter was placed at T4-5 interspace and 1.5% mepivacaine was infused (7 ml bolus and 5 ml x hr(-1) thereafter). After placing external pacemaker paddle, general anesthesia was induced with propofol 3 microg x ml(-1) and fentanyl 0.1 mg, and tracheal intubation was facilitated with vecuronium 6 mg. Anesthesia was maintained with propofol and fentanyl. After initiating one-lung ventilation, the patient developed Mobitz type II block with a heart rate of 30 beats x min(-1). External pacing was started (rate: 80 beats x min(-1), output: 150 mA). However, body movement associated with external pacing interrupted operative procedure, and blood pressure was not restored effectively. Therefore, external pacing was stopped and atropine and dopamine were administered. Mobitz type II block continued, but blood pressure and heart rate were maintained during the operation. Cardiac rhythm was restored the next morning without any treatment. Propofol, fentanyl, and thoracic epidural anesthesia could caused Mobitz type II block. External pacing should not be used for thoracic surgeries.

Download full-text PDF

Source

Publication Analysis

Top Keywords

type block
16
mobitz type
16
external pacing
16
heart rate
12
rate beats
12
beats min-1
12
blood pressure
12
block one-lung
8
one-lung ventilation
8
propofol fentanyl
8

Similar Publications

Purpose: Isocitrate dehydrogenase (IDH) mutation status serves as a crucial prognostic indicator for glioma, typically assessed via immunohistochemical analysis post-surgery. Given the invasiveness of this approach, perhaps we can utilise convenient and noninvasive magnetic resonance imaging (MRI) methods to predict IDH mutation status. However, the current landscape lacks a standardised MRI technique for accurately predicting IDH mutations.

View Article and Find Full Text PDF

Timelapse imaging using high-resolution peripheral quantitative computed tomography (HR-pQCT) has emerged as a noninvasive method to quantify bone (re)modelling. However, there is no consensus on how to perform the procedure. As part of the ASTEROID phase-2b multicenter trial, we used 29 same-day repeated scans from adults with osteogenesis imperfecta (OI) to identify a method that minimized measurement error.

View Article and Find Full Text PDF

Probing the properties of PTEN specific botulinum toxin type E mutants.

J Neural Transm (Vienna)

January 2025

Institut für Zellbiochemie, OE 4310, Medizinische Hochschule Hannover, 30623, Hannover, Germany.

Botulinum neurotoxins (BoNT) are established biopharmaceuticals for neuromuscular and secretory conditions based on their ability to block neurotransmitter release from neurons by proteolyzing specific soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Recently, a mutant catalytic domain of serotype E (LC/E) exhibiting 16 mutations was reported to cleave the phosphatase and tensin homolog (PTEN). This molecule represents an attractive new target in neurons as several reports support PTEN knockdown as a strategy to stimulate axonal regeneration after injury.

View Article and Find Full Text PDF

Modified Erector Spinae Block.

Cardiovasc Intervent Radiol

January 2025

Department of Diagnostic Imaging, Interventional Radiology, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, CABA, CP C1199ABB, Buenos Aires, Argentina.

View Article and Find Full Text PDF

Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!